

# Solomon Islands

Population 2018

<1 million

Estimates of TB burden <sup>o</sup> , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	0.48 (0.37–0.61)	74 (57–94)
HIV-positive TB incidence		
MDR/RR-TB incidence <sup>oo</sup>	0.011 (<0.01–0.021)	1.6 (0.61–3.2)
HIV-negative TB mortality	0.053 (0.034–0.076)	8.2 (5.2–12)
HIV-positive TB mortality	0 (0–0)	0 (0–0)

Estimated proportion of TB cases with MDR/RR-TB, 2018	
New cases	2.3% (0.92–4.3)
Previously treated cases	0% (0–41)

TB case notifications, 2018	
Total new and relapse	387
- % tested with rapid diagnostics at time of diagnosis	27%
- % with known HIV status	28%
- % pulmonary	72%
- % bacteriologically confirmed <sup>ooo</sup>	65%
- % children aged 0-14 years	17%
- % women	41%
- % men	42%
Total cases notified	391

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2018	80% (63–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	11% (7–17)

TB/HIV care in new and relapse TB patients, 2018		Number	(%)
Patients with known HIV status who are HIV-positive		0	0%
- on antiretroviral therapy		0	

Drug-resistant TB care, 2018	
% of bacteriologically confirmed TB cases tested for rifampicin resistance <sup>ooo</sup>	
- New cases	0%
- Previously treated cases	0%
Laboratory-confirmed cases*	MDR/RR-TB: 0, XDR-TB: 0
Patients started on treatment**	MDR/RR-TB: 0, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs	0

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2017	92%	373
Previously treated cases, excluding relapse, registered in 2017	100%	5
HIV-positive TB cases registered in 2017		0
MDR/RR-TB cases started on second-line treatment in 2016		0
XDR-TB cases started on second-line treatment in 2016		0

TB preventive treatment, 2018	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2019	
National TB budget (US\$ millions)	1.1
Funding source: 39% domestic, 61% international, 0% unfunded	

<sup>o</sup> Ranges represent uncertainty intervals

<sup>oo</sup> MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


<sup>ooo</sup> Calculated for pulmonary cases only

\* Includes cases with unknown previous TB treatment history

\*\* Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




Legend:  
■ Total TB incidence  
■ New and relapse TB cases notified  
■ HIV-positive TB incidence

(Rate per 100 000 population per year)



Legend:  
■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




Legend:  
■ Females ■ Males  Incidence

Treatment success rate (%)



Legend:  
■ New and relapse  
■ Retreatment, excluding relapse  
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

Total budget (US\$ millions)



Legend:  
■ Unfunded  
■ Funded internationally  
■ Funded domestically